Received Jan 22, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | UNK | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | UNK | — |
Breakthrough shingles; received 2nd dose of Shingrix 6 months after case of shingles; This non-serious case was reported by a pharmacist via sales rep and described the occurrence of shingles in a elderly female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix (unknown arm) and the 2nd dose of Shingrix. On an unknown date, 9 months after receiving Shingrix, the patient experienced shingles (Verbatim: Breakthrough shingles) and drug dose administration interval too long (Verbatim: received 2nd dose of Shingrix 6 months after case of shingles). The outcome of the shingles was resolved and the outcome of the drug dose administration interval too long was not applicable. The reporter considered the shingles to be related to Shingrix. The company considered the shingles to be related to Shingrix. Additional Information: GSK receipt date: 16-JAN-2026 The patient received 2nd dose of Shingrix 6 months after case of shingles. The batch number was not provided, and unable to contact the reporter.